Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382481 | 0.82 | TSHR (0.46) | KDM4EALDH1A1HTTPOLBPKM | |
| SCHEMBL24155179 | 0.76 | CHRNB2 (0.45) | KMT2AALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL24154668 | 0.76 | CHRNB2 (0.49) | KMT2AALDH1A1HPGDCHRNB2CHRNA4 | |
| SCHEMBL30116723 | 0.76 | CHRNB2 (0.49) | KMT2AALDH1A1HPGDCHRNB2CHRNA4 | |
| SCHEMBL15799144 | 0.72 | KMT2A (0.50) | RAB9AKMT2ADGAT1CHRNB2CHRNA4 | |
| SCHEMBL18518791 | 0.72 | KMT2A (0.50) | RAB9AKMT2ADGAT1CHRNB2CHRNA4 | |
| SCHEMBL25004995 | 0.72 | KMT2A (0.50) | RAB9AKMT2ADGAT1CHRNB2CHRNA4 | |
| SCHEMBL17259086 | 0.72 | KMT2A (0.50) | RAB9AKMT2ADGAT1CHRNB2CHRNA4 | |
| SCHEMBL15799143 | 0.72 | KMT2A (0.50) | RAB9AKMT2ADGAT1CHRNB2CHRNA4 | |
| SCHEMBL15805091 | 0.72 | KMT2A (0.50) | RAB9AKMT2ADGAT1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| WO-2021260029-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | TRHDE, CUTA, PIGS | RAB9A 391/4885KMT2A 808/4885KDM4E 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.